KBP Biosciences Pte. Ltd.

KBP Biosciences Pte. Ltd. is a Singapore-headquartered, clinical-stage biotechnology company dedicated to the discovery, development and commercialization of innovative small-molecule medicines for serious cardiorenal and infectious diseases with significant unmet medical need. The company describes itself as a global leader in drug discovery and development, built around an integrated pharmacology experimental platform and a proprietary compound library that allow it to identify and advance differentiated product candidates from the bench to the clinic. KBP's stated therapeutic focus spans hypertension, cardiorenal disease and infectious diseases. Its pipeline is composed of clinical and preclinical programs generated from its in-house R&D platform. The company positions itself as a world-class biotechnology research and development organization serving global markets, and it engages with the international clinical and scientific community — for example, as a corporate supporter of the Kidney Disease Clinical Trialists (KDCT) 2025 Workshop held in Washington DC, where its Chief Development Officer Fred Yang presented on estimands in kidney disease trials. KBP is a private company founded and led by Dr. Huang Zhenhua, who serves as founder and executive chairman. Its leadership team includes scientific and development executives such as Fred Yang, PhD, Chief Development Officer. The company's most publicly visible asset has been Ocedurenone, a small-molecule candidate that became the subject of a high-profile dispute with Novo Nordisk A/S after Novo Nordisk acquired the program and later terminated its development. That dispute has generated significant public attention. Novo Nordisk obtained a temporary injunction against KBP and Dr. Huang in the Singapore International Commercial Court, and both parties commenced arbitration proceedings. KBP has publicly contested Novo Nordisk's allegations, and in May 2026 the Singapore Court of Appeal maintained the temporary injunction pending final resolution of the arbitration while expressly noting that no finding of fraud or dishonesty had been made against KBP or Dr. Huang. KBP has stated that it will continue to defend its position in arbitration and to pursue paths forward for Ocedurenone.

KBP Biosciences Pte. Ltd. is a Singapore-headquartered clinical-stage biotechnology company. It was founded by Dr. Huang Zhenhua, who serves as founder and executive chairman, and it has built its identity around an integrated drug discovery and development platform combining pharmacology experimentation with a proprietary compound library. The company's stated mission is to provide innovative therapies for unmet medical needs, with a therapeutic focus on hypertension, cardiorenal disease and infectious diseases. KBP describes itself as a global leader in drug discovery and development and as a world-class biotechnology research and development organization. Its platform is designed to identify and progress product candidates with significant differentiation, and it has established a pipeline of clinical and preclinical programs. The company operates with a global orientation, aiming to bring new drugs from bench to clinic around the world. The company's most prominent program has been Ocedurenone, a small-molecule candidate in the cardiorenal space. Ocedurenone became the center of a public dispute after Novo Nordisk A/S acquired the program and subsequently terminated its development, citing futility. KBP has publicly contested the basis for that decision. According to KBP's public statements, Novo Nordisk terminated the trial in the eighth month after acquiring Ocedurenone; KBP has pointed to a statistical error later identified by Parexel International (IRL) Ltd. in the data pooling process, after which, KBP says, Ocedurenone met only one of two futility criteria and remained worth developing as planned rather than being worthless. KBP has also cited independent statements from trial steering committee members Dr. Bertram Pitt and Dr. Janet Wittes, including a December 18, 2024 public letter stating that neither Novo Nordisk nor KBP had provided convincing evidence that results from a Bulgarian trial site were falsified. The dispute moved into the courts and then into arbitration. Novo Nordisk obtained a temporary injunction in the Singapore International Commercial Court against KBP and Dr. Huang. KBP commenced arbitration before Novo Nordisk did, and both parties have ongoing arbitration proceedings. On August 13, 2025, KBP issued a statement responding to a further SICC ruling maintaining the temporary injunction in support of the arbitrations, emphasizing that the SICC's conclusions would be reviewed by the arbitral tribunal, which has more time and can hear live testimony. On May 21, 2026, KBP issued a statement addressing the Singapore Court of Appeal's decision to maintain the temporary injunction pending final resolution of the arbitration. The Court of Appeal expressly observed that the Singapore court had made no finding of fraud or dishonesty against the company or Dr. Huang, and that the merits of Novo Nordisk's claims and KBP's defenses remain for final adjudication in arbitration. KBP stated that it was disappointed with the decision to maintain the injunction but noted that the substantive issues must be determined by the arbitral tribunal. KBP has said it will continue to defend itself, to seek dialogue with Novo Nordisk's new management about Ocedurenone's future, and to assert its rights in the legal proceedings, including possible appeals. Beyond the litigation, KBP continues to present itself as an active participant in the global clinical research community. In April 2025 it announced that it was a corporate supporter of the Kidney Disease Clinical Trialists 2025 Workshop held in Washington DC, where its Chief Development Officer Fred Yang, PhD, presented an industry perspective on estimands in clinical trials for safety evaluation. Dr. Huang has stated that KBP will continue to work with physicians and patients to find the best treatment options for patients with cardiovascular and chronic kidney disease.

• Trial steering committee members Dr. Bertram Pitt and Dr. Janet Wittes issued a public letter stating neither Novo Nordisk nor KBP provided convincing evidence that results from a Bulgarian trial site were falsified.

• KBP announced it was a corporate supporter of the Kidney Disease Clinical Trialists 2025 Workshop in Washington DC, April 4-5, 2025.

• KBP issued a statement responding to a further SICC ruling maintaining the temporary injunction in support of the arbitrations with Novo Nordisk.

• KBP issued a statement on the Singapore Court of Appeal's decision to maintain the temporary injunction pending arbitration, noting no finding of fraud or dishonesty against KBP or Dr. Huang.

Global clinical-stage biotech focused on differentiated small-molecule therapies for cardiorenal and infectious diseases.

• Ocedurenone

  Small-molecule cardiorenal candidate acquired by Novo Nordisk and later terminated; subject of ongoing arbitration between KBP and Novo Nordisk.

• Dispute with Novo Nordisk over Ocedurenone

Read more

1. 1KBP BIOSCIENCESkbpbio.com
2. 2KBP as Corporate Supporter of the KDCT 2025 Workshopkbpbio.com
3. 3Singapore Court of Appeal Notes No Finding of Fraud Against KBP or Dr. Huang; Dispute with Novo Nordisk Undergoing Arbitration Proceedingskbpbio.com
4. 4关于诺和诺德禁令的争议进入仲裁程序，KBP将持续抗辩kbpbio.com
5. 5KBP Biosciences (Singapore)wikidata.org